34 results about "Multiple drug resistance" patented technology

The invention provides a method for synchronously and rapidly detecting Escherichia coli and multiple drug-resistant genes thereof, which comprises the following steps: culturing a sample at night to obtain a bacterial solution to be detected, adding a buffer solution and a metal bath, centrifuging, taking a supernatant, detecting by micro-fluidic, optimizing the extraction process of nucleic acid in the sample, designing an optimal RPA primer probe group, and detecting the multiple drug-resistant genes of the Escherichia coli. A reasonable RPA coupled microfluidic detection system is established, synchronous and rapid detection of the escherichia coli uidA and I-type integrase gene intI1 thereof and drug-resistant genes sul1 and aadA5 is realized, the specificity is high, the sensitivity is high, the reaction time is short, the operation is convenient, and a method support is provided for monitoring and prevention and control of food-borne drug-resistant bacteria.

The utility model discloses a multi-bin paper-based micro-fluidic chip for visual detection of bacterial drug resistance. The multi-bin paper-based micro-fluidic chip comprises a hydrophilic paper base, the detection mechanism is a hydrophilic channel established on the hydrophilic paper base; the detection mechanism comprises a sample adding bin and an anti-overflow bin, and the appearance of the anti-overflow bin is circular; one end of the anti-overflow channel is communicated with the sample adding bin, and the other end of the anti-overflow channel is communicated with the anti-overflow bin; the appearance of each reaction bin is an isosceles trapezoid; the plurality of reaction bins are uniformly distributed in a fan shape by taking the circle center of the sample adding bin as a central original point; one end of each diffusion channel is communicated with the reaction bin, and the other end of each diffusion channel is communicated with the sample adding bin; wherein the diffusion channels and the reaction bins are arranged in a one-to-one correspondence manner; the hydrophobic barrier structure is a hydrophobic area formed on the hydrophilic paper base through wax spraying printing along the outer edge of the detection mechanism. According to the multi-bin paper-based micro-fluidic chip for visual detection of bacterial drug resistance, provided by the utility model, rapid, high-throughput and low-cost detection of multiple bacterial drug resistance can be realized.

The application discloses application of antibacterial peptide BMAP-28 and antibiotics in combined preparation of antibacterial drugs and belongs to the technical field of biological medicine. The antibiotics are selected from one or more of the following: ciprofloxacin, gentamicin and cefixime. The application combines the antibacterial peptide BMAP-28 with antibiotics such as ciprofloxacin and gentamicin, finds that the combination has a significant synergistic antibacterial effect on Enterobacter sakazii, can greatly save the dosage of the drug, reduce the toxic side effect and block the evolution process of drug resistance. Through the destruction of the bacterial cell membrane and the assistance of the antibiotic effect, the combination can effectively overcome the multiple drug resistance, widen the antibacterial spectrum and has a wide clinical application prospect.

The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof having potent antibacterial activity against klebsiella pneumoniae, in particular against multi-drug resistant klebsiella pneumoniae strains. The invention also relates to application of the monoclonal antibody or the antigen binding fragment thereof in treatment, prevention and diagnosis of Klebsiella pneumoniae infection, especially Klebsiella pneumoniae related diseases.

The invention belongs to the technical field of animal models, and relates to a construction method of a febrile infection associated epileptic syndrome (FIRES) animal model. The method comprises the following steps: firstly, injecting lipopolysaccharide (LPS) into the abdominal cavity of a normal mouse to induce systemic inflammatory reaction, and simulating a fever process in combination with thermal exposure; 4-aminopyridine (4-AP) is injected into the brain of the mouse 24 hours after the injection of lipopolysaccharide (LPS) is finished to induce the occurrence of the epilepsy syndrome related to the hot infection of the normal mouse, and the model of the epilepsy syndrome related to the hot infection of the mouse is constructed. Typical characteristics of FIRES are successfully simulated: precursory fever (2 weeks to 24 hours before attack), an electroencephalogram (EEG) shows beta-delta complex waves and rhythmic sharp waves of extreme delta brushing, and a multi-drug-resistant epileptic state. The invention provides the novel construction method of the mouse fever infection related epileptic syndrome model, the model characteristics are typical, the modeling success rate is high, and the modeling period is short. Wide application prospects are realized.

The invention discloses application of gentamicin and ceftazidime in enhancing the drug sensitivity of serratia marcescens, and belongs to the field of biological medicine. The serratia marcescens is a strain carrying drug-resistant genes such as OqxB and mdtC, the mass ratio of gentamicin to ceftazidime is (1: 10)-(1: 50), the synergistic effect of gentamicin and ceftazidime is the strongest under the ratio, the sensitivities of serratia marcescens to gentamicin and ceftazidime can be recovered by 12.5 times and 42 times respectively, MBC is synchronously and greatly reduced, and the serratia marcescens has the dual effects of drug sensitivity enhancement and infection treatment; the single dosage is reduced, so that the cost is reduced, and the potential damage of the medicine to a host is reduced while the treatment effect is ensured. The prodigiosin is effective to serratia marcescens carrying various drug-resistant genes such as OqxB, mdtC, AAC (6 ')-Ic, KdpE and CpxA, cost is saved for prevention, control and treatment of serratia marcescens in animal husbandry, and important reference is provided for safe extraction and utilization of prodigiosin and clinical treatment of human serratia marcescens infection.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, hybridoma cell strains thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies is shown as SEQ NO:1-SEQ NO:56, preservation numbers of the hybridoma cell strains are CCTCC:C2023365, CCTCC:C2023366, CCTCC:C2023367, CCTCC:C2024340, CCTCC:C2024341, CCTCC:C2024342 and CCTCC:C2024343 respectively, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, are favorable for typing of Klebsiella pneumoniae in clinic, and can prove excellent effects of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies in preventing and treating infection of Klebsiella pneumoniae in in-vivo and in-vitro tests, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating Klebsiella pneumoniae infection, and has important value for developing a new generation of Klebsiella pneumoniae drugs.

This invention belongs to the field of biodetection technology, specifically disclosing a primer-probe composition and kit for detecting drug-resistant gene mutations in Helicobacter pylori. The composition comprises two sets of primers and probes, using the probe melting curve method as its principle. The composition and universal PCR reagents are used to detect multiple drug resistance mutations in the quinolone resistance gene gyrA and the clarithromycin resistance gene 23S rRNA of Helicobacter pylori in biological samples. This overcomes the limitation of existing methods that only detect single mutation sites in a single tube for Helicobacter pylori drug resistance genes, providing a new, rapid, and efficient method for detecting Helicobacter pylori drug resistance genes.

The application provides a multifunctional nano drug delivery system based on iron-doped MOF and a preparation method and application thereof. The system comprises: an Fe / MOF core loaded with a chemotherapeutic drug and an HO-1 inhibitor; a PDA coating layer coated on the surface of the Fe / MOF core for providing near-infrared light heat conversion capability and surface modification interface; and E3 aptamer covalently coupled on the PDA coating layer, constituting a synergistic nano platform with active targeting, pH / NIR dual-responsive drug release, chemical kinetics therapy, ferroptosis sensitization, photothermal therapy and immune regulation functions. The nano system can realize efficient accumulation at the tumor site through active targeting mediated by E3 aptamer, and controllably release drugs under an acidic microenvironment or near-infrared light. A new strategy for multi-mechanism synergistic treatment is provided to overcome the multiple drug resistance and immunosuppression of mCRPC, and has important clinical application prospects.

The invention discloses a multi-drug-resistance gene detection system and method based on a suspension array technology and application. The multi-drug-resistance gene detection system comprises coding microspheres, a primer group, a fluorescence labeled anti-Tag ssDNA molecule and phycoerythrin. The invention constructs a detection method aiming at a plurality of bacteria and drug-resistant genes by a suspension array technology, designs a plurality of pairs of specific primers of bacteria and drug-resistant genes with Tag labels, captures Tag labeled products after multiple PCR amplification by anti-Tag fixed on a suspension array, realizes accurate detection, and has the advantages of high specificity, high sensitivity, high sensitivity and high sensitivity. According to the present invention, with the kit, the four types of bacteria (E. coli, A. brumanni, K. pneumonae and P. aeruginosa) and the eight types of drug-resistant genes (blaKPC-2-like, blaNDM-like, blaOXA-48-like, blaOXA-23-like, blaIMP-like, blaVIM-like, blaCMY-2-like and blaADC-68-like) can be simultaneously detected in the same reaction system, such that the reagent consumption is reduced, the cost is reduced, and the detection time is shortened.

An antifungal compound / conjugate is derived from quercetin, a naturally occurring flavonoid, through a strategic conjugation approach. The resulting quercetin conjugate exhibits enhanced antifungal activity and improved pharmacological properties compared to its parent molecule. The conjugate demonstrates potent efficacy against a range of drug-resistant fungal pathogens, including Candida auris, a critical threat in clinical settings due to its multidrug resistance. The invention also encompasses methods for synthesizing the conjugate, formulating the conjugate in a pharmaceutical preparation, and methods of use for treatment and prevention of superficial and systemic fungal infections.

The invention relates to the technical field of micro-fluidic electrochemical detection, in particular to a multi-channel micro-fluidic chip for detecting various drug-resistant mycobacterium tuberculosis as well as a use method and application of the multi-channel micro-fluidic chip. The multi-channel micro-fluidic chip comprises a splitting area and a sample mixing area, the splitting area comprises a sample injection hole and a DNA splitting chamber which are communicated in sequence, the sample mixing area comprises a sample mixing chamber, and the DNA splitting chamber and the sample mixing chamber are communicated through a first micro-channel; the electrode array area comprises a plurality of reaction detection chambers and detection electrodes, the detection electrodes are in one-to-one correspondence with the reaction detection chambers and are in contact with the inner spaces of the reaction detection chambers, the electrodes are modified with signal amplification probes, Cas12a-crRNA compounds are preloaded on the surfaces of the electrodes, and the reaction detection chambers are communicated with the sample mixing chamber through a second micro-channel. Multiple channels are designed, synchronous detection of multiple drug-resistant genes is achieved, integration of clinical sample treatment, DNA acquisition, DNA thermal denaturation treatment and DNA detection is achieved, operation is easy and smooth, and clinical diagnosis and medication guidance of tuberculosis drug resistance can be well served.

The application discloses K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, a hybridoma cell strain thereof and application of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, sequence information of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody is shown in SEQ NO:25-SEQ NO:32, the hybridoma cell strain has a preservation number of CCTCC NO:C2023296, the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, is favorable for typing of Klebsiella pneumoniae in clinic, and it can be proved in in-vivo and in-vitro tests that the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody has excellent effects in preventing and treating infection of the K47 type Klebsiella pneumoniae, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating infection of Klebsiella pneumoniae, and has important value for development of a new generation of Klebsiella pneumoniae drugs.

A compound as shown in the following formula (I) and its racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph or pharmaceutically acceptable salt thereof, the compound is an analogue of eribulin, has good anticancer activity, can overcome multiple drug resistance and maintain high cytotoxicity.

The invention relates to a broad-spectrum antibacterial peptide bsa091 and application thereof, and relates to the technical field of biology. The antibacterial peptide has broad-spectrum antibacterial activity, can inhibit gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa, and fungi such as candida auriculata and candida albicans, and has high antibacterial activity. The compound has a relatively strong inhibition effect on clinically separated drug-resistant strains with multiple drug resistance. In addition, the antibacterial peptide is low in hemolytic activity, small in toxicity, short in synthetic sequence, small in molecular weight and easy to chemically synthesize. And the in-vivo safety is ensured while efficient sterilization is realized.

The application discloses application of gentiopicroside in preparation of a medicine for preventing and controlling viral or bacterial infection. At present, the main prevention strategy for infectious diseases is to develop vaccines, and corresponding antibiotic treatment can be considered for bacterial infection treatment, but at present, antibiotics also have the problem of multiple drug resistance, and specific drugs for viral infection are still lacking. The application starts from the angle of improving the body's own anti-infection immunity, finds effective components for preventing and controlling infection from natural compounds, and provides a new candidate medicine for preventing and controlling infection.

The present application relates to the technical field of biological medicine, and provides a bacteriophage for lysing high-toxicity multi-drug resistant Klebsiella pneumoniae and application thereof.The bacteriophage is Klebsiella pneumoniae phage vB_KpnP_XY3, and the preservation number is CCTCC NO: M 2025022.The bacteriophage can lyse high-toxicity multi-drug resistant Klebsiella pneumoniae 32416 carrying blaTEM, blaSHV, phoQ, pmrB drug resistance genes and rmpA, kfuBC, ybtA, iro-NB, fim-H, ureA, uge, wabG virulence genes, and has great potential in clinical application, and is an ideal choice for replacing antibiotics to treat multi-drug resistant bacteria.The bacteriophage vB_KpnP_XY3 not only widens host spectrum and lysis capacity, but also has broad application potential in clinical treatment of multi-drug resistant Klebsiella pneumoniae infection and environmental purification.

The application provides a method for detecting 19 Neisseria gonorrhoeae drug resistance site mutations. The method uses multiplex PCR-mass spectrometry to detect 19 Neisseria gonorrhoeae drug resistance site mutations. The detection method comprises the following steps: 1) designing primers for different drug resistance sites; 2) multiplex PCR amplification reaction; 3) shrimp alkaline phosphatase treatment; 4) single base extension reaction; 5) resin desalting purification; and 6) mass spectrometry detection.

The present application relates to the field of biotechnology, in particular to a kind of amplification primer combination and kit for detecting mycobacterium tuberculosis drug resistance gene.The kit is based on nanopore sequencing technology, comprising 20 pairs of primers designed, screened and verified.During detection, these primer mixtures are used, and the DNA of the sample to be tested is amplified by multiplex PCR, each pair of primers amplifies a nucleotide sequence or the entire gene full-length sequence during the reaction, then the high-throughput and long fragment reading characteristics of nanopore sequencing technology are used to obtain the gene sequence, and finally the sample to be tested is determined by bioinformatics analysis.The method of the present application can simultaneously complete the amplification and detection of multiple genes under the same reaction conditions, does not need to culture mycobacterium tuberculosis, can identify mycobacterium tuberculosis complex, and detect multiple drug resistance genes, with the characteristics of multiple indicators, rapid, strong specificity, high sensitivity and the like.

An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.

The invention relates to the technical field of streptococcus suis drug resistance gene detection, and particularly discloses a streptococcus suis drug resistance gene sextuple PCR detection kit and application thereof. The core of the kit is a specific primer combination, the nucleotide sequences of the specific primer combination are as shown in SEQ ID NO: 1-12, and the specific primer combination respectively aims at six key drug-resistant genes of streptococcus suis: ermB, tet (O), patB, aac (6 '')-Ie-ah (2 ')-Ia, optrA and lsa (E). By optimizing the primer concentration and reaction conditions, an efficient and stable sextuple PCR detection system is established, and amplification and detection of the six genes can be synchronously completed in a single reaction. The method has the advantages of high specificity, high sensitivity, good repeatability, simplicity and convenience in operation and the like. A high-throughput and low-cost molecular detection tool is provided for rapid diagnosis, medication guidance and epidemiological monitoring of streptococcus suis clinical multiple drug resistance, and the application prospect is wide.

The invention discloses application of a folium sennae extract in preparation of a medicine for preventing and treating helicobacter pylori infection. The folium sennae alcohol extract disclosed by the invention shows an obvious bactericidal effect on multi-drug-resistant helicobacter pylori; when being combined with amoxicillin, the compound has a synergistic antibacterial effect on general helicobacter pylori and helicobacter pylori with drug resistance to amoxicillin. According to the invention, a new drug choice is provided for treatment of patients suffering from mild symptoms of H.pylori infection and drug resistance, and unique advantages are played in graded diagnosis and treatment and drug-resistant H.pylori treatment.

The invention provides a method for simultaneously and rapidly detecting vibrio parahaemolyticus and multiple drug-resistant genes thereof, which comprises the following steps: preparing vibrio parahaemolyticus immunomagnetic beads by coupling biotinylated vibrio parahaemolyticus polyclonal antibodies with streptavidin nano magnetic beads, and carrying out immunocapture on the vibrio parahaemolyticus. According to the present invention, the RPA-coupled micro-fluidic detection system is designed, the capture condition and the nucleic acid extraction process are optimized, the reasonable RPA-coupled micro-fluidic detection system is designed, the toxR gene of the vibrio parahaemolyticus and the three most common drug-resistant genes floR, sul1 and qnrA are synchronously detected, and the important significance is provided for solving the drug resistance problem of marine product pathogenic microorganisms and ensuring the human health.

The application discloses K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, a hybridoma cell strain thereof and application of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, sequence information of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody is shown in SEQ NO:17-SEQ NO:24, the hybridoma cell strain has a preservation number of CCTCC NO:C2023311, the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, is favorable for typing of Klebsiella pneumoniae in clinic, and it can be proved in in-vivo and in-vitro tests that the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody has excellent effects in preventing and treating infection of the K47 type Klebsiella pneumoniae, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating infection of Klebsiella pneumoniae, and has important value for development of a new generation of Klebsiella pneumoniae drugs.

The application discloses K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, a hybridoma cell strain thereof and application of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, sequence information of the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody is shown in SEQ NO:33-SEQ NO:40, the hybridoma cell strain has a preservation number of CCTCC NO:C2023313, the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody provided by the application can be specifically combined with the capsular polysaccharide of Klebsiella, is favorable for typing of Klebsiella pneumoniae in clinic, and can prove that the K47 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody has excellent effects in preventing and treating infection of the K47 type Klebsiella pneumoniae in in-vivo and in-vitro tests, provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating infection of Klebsiella pneumoniae, and has important value for development of a new generation of Klebsiella pneumoniae drugs.

The invention relates to a broad-spectrum antibacterial peptide bsa051 and application thereof, and relates to the technical field of biology. The antibacterial peptide has broad-spectrum antibacterial activity, can inhibit gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa, and fungi such as candida auriculata and candida albicans, and has high antibacterial activity. The compound has a relatively strong inhibition effect on clinically separated drug-resistant strains with multiple drug resistance. In addition, the antibacterial peptide is low in hemolytic activity, small in toxicity, short in synthetic sequence, small in molecular weight and easy to chemically synthesize. And the in-vivo safety is ensured while efficient sterilization is realized.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, a hybridoma cell strain thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody is shown in SEQ NO:9-SEQ NO:16, the hybridoma cell strain has a preservation number of CCTCC:C2023366, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, is favorable for typing of Klebsiella pneumoniae in clinic, and it can be proved in in-vivo and in-vitro tests that the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody has excellent effects in preventing and treating infection of the K64 type Klebsiella pneumoniae, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating infection of Klebsiella pneumoniae, and has important value for development of a new generation of Klebsiella pneumoniae drugs.

This invention belongs to the field of hydrogel dressing technology, specifically disclosing a hydrogel dressing loaded with fresh tea leaf nanoparticles, its preparation method, and its application. The preparation method includes the following steps: preparing fresh tea leaf nanoparticles; preparing a carboxymethyl chitosan solution; preparing a carboxymethyl chitosan solution containing fresh tea leaf nanoparticles; preparing an oxidized hyaluronic acid solution; and mixing the obtained carboxymethyl chitosan solution containing fresh tea leaf nanoparticles with the oxidized hyaluronic acid solution to obtain the hydrogel dressing loaded with fresh tea leaf nanoparticles. This invention utilizes the above-mentioned hydrogel dressing loaded with fresh tea leaf nanoparticles, its preparation method, and its application. The preparation process is simple and easy to control, and is not limited by problems such as increased antibiotic resistance and frequent dressing changes. It promotes wound healing, eliminates harmful bacteria, effectively resists multidrug-resistant bacterial infections, and simultaneously promotes wound healing and skin regeneration.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, a hybridoma cell strain thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody is shown in SEQ NO:33-SEQ NO:40, the hybridoma cell strain has a preservation number of CCTCC:C2024341, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, is favorable for typing of Klebsiella pneumoniae in clinic, and can prove that the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibody has excellent effects in preventing and treating infection of the K64 type Klebsiella pneumoniae in in-vivo and in-vitro tests, provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating infection of Klebsiella pneumoniae, and has important value for new generation Klebsiella pneumoniae drug development.

The present application relates to the field of biotechnology, in particular to a fusion plasmid and its application in gene transfer and protein expression. The present application provides a novel IncI1 and IncHI2 / IncHI2A type self-transmissible fusion plasmid containing NDM-13 and OXA-10 from clinical Salmonella, which also carries other multiple drug resistance genes and shows resistance to multiple antibiotics. Salmonella is a pathogenic bacterium of zoonosis and has the ability to infect humans and livestock. Salmonella carrying the plasmid has the potential to cause outbreaks, and active research is needed to prevent the occurrence of outbreaks.